Are Biosimilars the Next Big Growth Opportunity for the Pharmaceutical Industry?

As top-selling biologics begin to lose patent protection, some drug makers are investing heavily to meet anticipated demand for biosimilars. Yet the high cost and complexity of these new drugs pose a risk to expected profits.

Key Takeaways

  • Biologics are a class of drugs derived from the cells of genetically modified living organisms. They’re orders of magnitude more complex than conventional, chemically synthesized drugs, and hence more costly to produce and to purchase.
  • Biologics are also generally more effective at treating serious medical conditions such as cancers and autoimmune disorders. Seven of the top ten best-selling drugs in the world in 2017 were biologics, including AbbVie’s Humira, the world’s top-selling drug by far.
  • As patents for biologics begin to expire, some drug companies are investing heavily in new production facilities in a bid to profit from the anticipated rise in demand for biosimilars—the cheaper copies of biologics. Yet entering this market represents a considerable bet because a biologics facility can cost five times as much as a conventional pharmaceutical plant. Success at developing a biosimilar is also less likely than a conventional drug.
  • Because the biosimilar industry is still nascent, it is difficult to discern whose investments will be profitable. On the other hand, makers of bioreactors, filtration devices, and other sophisticated equipment needed to produce biologics are the early beneficiaries of the investment boom.

Harding Loevner Health Care Analysts Patrick Todd, CFA and David Glickman, CFA talk with Deputy Manager of Research Tim Kubarych, CFA about the fast-growing biosimilars industry. The transcript, lightly edited for clarity, follows.

Tim Kubarych: We all know that when we walk into a Walgreens and see a bottle of Advil next to a bottle of generic ibuprofen that the generic industry has made a big impact on drug pricing. But those are small-molecule or chemical drugs. What are biosimilars, and how is the biosimilar industry different from the generics small-molecule industry?

Patrick Todd: Before we talk about biosimilars I think we should define biologics. Biologics are proteins that are grown in cells and then purified and made into drugs. In contrast, conventional small-molecule drugs are chemically synthesized, so the manufacturing process for biologics is significantly more intensive.

Biosimilars are copies of biologic drugs and the barriers to entry, given the difficulty of manufacturing those drugs, are significantly higher. There are also some regulatory barriers. Because they’re grown in cells, they end up being a bit different than the original reference drug, so manufacturers of biosimilars have to do clinical trials to prove that the drug is efficacious.

David Glickman: Whereas for a generic small-molecule drug, they’re only required to conduct small studies to verify the levels of that drug in the bloodstream, which is much faster and cheaper.

Biosimilars Are Similar, Not Identical

Credit: Mind The Byte

TK: With this increased complexity in manufacturing, what kind of companies compete in the biosimilars space, and what have been their capital expenditure plans to meet this demand?

PT: There are companies doing the research and actually manufacturing the biologics, companies like Celltrion and Samsung, which are Korean companies. Some drug innovators are also getting into biosimilars—companies like Pfizer, for example. And then there are a lot of companies that are supplying the bioreactors, purification equipment, and other supplies needed to grow biosimilars. These companies include Sartorius and Merck KGaA, which are German companies, Thermo Fisher in the US, Danaher, and even GE Healthcare.

The capital expenditure plans looking forward are pretty robust. If you look at the top-selling drugs in the world today, they’re more or less all biologics and they’re all coming off patent. So we know that demand for biosimilars is going to rise, and companies are investing in the manufacturing capacity to meet that demand.

Top-Selling Pharmaceuticals Globally, 2017

Source: PharmaCompass, IgeaHub

TK: The patent expiry of a lot of these more-complex molecules should bode well for the manufacturers of biosimilars, but will the companies be able to profit from that development or are they competing away this profit pool?

DG: We’re still very early on in this process. In Europe, so far we’ve seen biosimilars priced at a sharp reduction from the original innovator price. However, in the US we’re seeing smaller discounts. In the US, typically what you’d see in small-molecule drugs is the original drug innovator would remain on the market at the branded price, generics would then enter with a 95%+ discount, and the innovator would lose almost all of that revenue within a few quarters. To produce biosimilars, pharma companies need to make a much more substantial investment, so they don’t want to price their products at a 90%+ discount. Instead, they may start with a 25–30% discount, so pricing will probably come down more gradually.

“I think the biggest risk is an issue with the FDA or the European Medicines Agency that causes the biosimilar production ramp to slow down.”

It’s also worth noting that sometimes it’s worthwhile for the innovator to compete on price. We see that currently with Johnson & Johnson and Remicade in the US. AbbVie has said that with Humira going biosimilar in about five years that they will also compete on price. The established branded manufacturers already have the manufacturing capacity, so in some cases it makes sense for them to compete on price, whereas in the small-molecule space it doesn’t make any sense, they just let it go.

TK: The high barriers to entry due to manufacturing complexity as well as more-stable prices seems to bode well for the profitability of the industry. Are there any risk factors that investors should be concerned about?

PT: The biggest risk in my opinion is—because they’re so difficult to manufacture—there could be an adverse event at a plant and the drug is going to get pulled from the market, which could lead to a broader distrust of biosimilars. So I think the biggest risk is that there’s some issue with the FDA or maybe the European Medicines Agency that causes the biosimilar production ramp to slow down.

DG: I also see a risk on the positive side. Within the US right now there are no guidelines on interchangeability, so if a doctor writes a prescription for something where a biosimilar is available, a patient would only get that biosimilar if the physician specifies it by name. Whereas for a small-molecule drug like Lipitor, if the physician just writes “Lipitor” a patient will most likely get the generic automatically. The executive branch in the US is working on guidelines for interchangeability, and when that happens it should relieve one of the bottlenecks to biosimilar penetration.

TK: What are the key takeaways when thinking about investing in biosimilars?

PT: I think the most attractive space is the supplier companies—I use the analogy of selling picks and shovels to gold miners. So that’s companies like Sartorius, Merck KGaA, Thermo Fisher, and Danaher. The suppliers are actually very concentrated and all manufacturers of biosimilars need to buy the bioreactors, the supplies, the filtration equipment, so the supplier companies will definitely benefit from this big uptick in biosimilar growth.

The Biosimilars Landscape

DG: And I would mention that I think it’s healthy for the pharmaceutical industry overall for biosimilar penetration to increase. When biologics were first approved around the turn of the century, it was thought they could have a lifespan that was closer to indefinite. Now we know that once patents lapse, biologics innovators can get real competition, which frees up money in the system to pay for new innovative drugs. So it’s a natural evolution of the system.

What did you think of this piece?


Deputy Manager of Research Timothy Kubarych, CFA and Analysts Patrick Todd, CFA and David Glickman, CFA contributed research and viewpoints to this piece.


The “Fundamental Thinking” series presents the perspectives of Harding Loevner’s analysts on a range of investment topics, highlighting our fundamental research and providing insight into how we approach quality growth investing. For more detailed information regarding particular investment strategies, please visit our website, Any statements made by employees of Harding Loevner are solely their own and do not necessarily express or relate to the views or opinions of Harding Loevner.

Any discussion of specific securities is not a recommendation to purchase or sell a particular security. Non-performance based criteria have been used to select the securities identified. It should not be assumed that investment in the securities identified has been or will be profitable. To request a complete list of holdings for the past year, please contact Harding Loevner.

There is no guarantee that any investment strategy will meet its objective. Past performance does not guarantee future results.

© 2024 Harding Loevner

Additional Articles

Fundamental Thinking

The New Retail: Why the Future of Shopping Will Be...

Fundamental Thinking

Why Battling Bugs Is a Booming Business, and May Be...

Fundamental Thinking

A Runway to Growth for Airport Services Companies